Delivering Next-Gen
Integrin Therapeutics
Validated targets
Cutting-edge therapeutics
Novel development system
What we Do
In the realm of proteins, location plays a crucial role. Integrins, much like antibodies binding to antigens, depend on ligand partners to carry out their functions effectively.
While many companies focus on blocking these interactions with antagonists, this approach can also disrupt healthy cell functions.
At AlloSite, we take a different approach. Instead of using antagonists, we target allosteric sites, strategically distant from critical regions, to enhance (re: agonize) integrin functionality.
This unique strategy allows cells to maintain their optimal function while promoting the desired therapeutic effects.
Allosteric Binding
Integrin Activation
Therapeutic action with less side-effects
Projected embedding from our own therapeutic transcriptomics
R & D
Fully equipped BSL-2 facility and a suite of proprietary assays that complement our unique AI approach
Proprietary Assays
Optimized suite of assays for therapeutic discovery and customized machine learning models for therapeutic optimization
Proprietary AI - Machine Learning
In-house trained protein natural language modelling delivers faster optimization of integrin activating antibodies
Process Expertise
Integrin and therapeutic expertise enable novel integrin constructs, AI-optimized therapeutics
All with a fully defined workflow
Proprietary AI models in R&D
The incorporation of our AI / machine learning methodology brings significant advantages to our process.
One notable benefit is its remarkable speed. At AlloSite, we utilize a suite of natural language and deep learning models to accelerate traditional therapeutic development significantly.
Therapeutic Discovery
Integrin Structure-function Modelling
Antigen Engineering
Antibody Targeting, Structure, and Binding
Therapeutic Development
Zero-shot CDR Grafting
Rapid Affinity Maturation
Immunogenicity Reduction
a priori Manufacturing Optimization
Antigen Engineering
Integrin Modularity
Integrins, existing as pairs, comprise at least 24 distinct combinations within the human body.
Though some integrins may share similarities, each plays unique roles, and specific integrins are associated with different diseases.
Our approach involves targeting both α and β chains across various integrin pairs. By leveraging our platform, we can effectively address a broad spectrum of indications, ranging from oncology to autoimmune conditions.
Modular AI platform is target agnostic
Wide range of targets potentiates wide range of indications
Have a question?
Want to chat? Have some feedback?
Browse our white papers
We have put together some material to get you started. We hope it is as exciting to you as it is to us.
© 2023 AlloSite Therapeutics. All rights reserved.